#ESMOAI25: Explore the latest AI-driven innovations in #oncology, brought to you by the #ESMOAmbassadors. Join the conversation on digital transformation in #CancerCare. #HealthAI
🔗 https://ow.ly/WoBr50XmYhI
🗞️ Check out my short #ESMODailyReporter editorial on early data from a first-in-human TCR-T therapy targeting KRAS G12V in advanced pancreatic & colorectal cancer, presented today by Dr Bai from Zhejiang University.
#ESMO25
#CellTherapy
#ESMOAmbassadors
@myesmo.bsky.social
@myesmo.bsky.social is where everything began, my first international oral presentation as a resident in medical oncology, my first international role as chair, discussant, invited speaker.
I will always be grateful to #ESMO!
#myESMOStory
#ESMO25
#ESMOAmbassadors
It’s great to see a friend and colleague growing within @myesmo.bsky.social!
#ESMO25
#myESMOStory
#ESMOAmbassadors
James Harding presents phase 1 data showing a manageable safety profile and promising efficacy in advanced #PDAC at #ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Do-Youn Oh discusses abstracts on #biliary tract cancer #BTC #CCA orally presented at #ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Michele Reni presents novel findings from the #CASSANDRA phase 3 study of perioperative treatment in #PDAC
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
IMMUNOBIL phase 2 study of immunotherapy #STRIDE for patients with previously treated advanced #BTC #CCA. Negative study but a subgroup of patients seem to benefit, we need biomarkers.
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Phase 2-3 ZSAB-neoGOLP trial of #neoadjuvant GOLP regimen for resectable i#CCA with high-risk features for recurrence. A positive interim analysis, but not a standard regimen. Novel approaches are needed.
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Milind Javle presents the results of #tinengotinib in patients with #CCA #BTC and #FGFR2 gene fusions previously treated with other FGFR inhibitors at #ESMO25
#ESMOAmbassadors @myesmo.bsky.social
@arndtvogel.bsky.social discusses #ABC-HCC and #TALENTop studies and puts them into the context.
Positive studies, potential novel strategies, still open questions.
Key message, #MDT is key in the management of patients with #HCC.
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Hui-Chuan Sun presents the #TALENTop phase 3 study of atezolizumab-bevacizumab followed by surgery in locally advanced #HCC.
Positive study, #MDT discussion is key!
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Peter Galle presents ABC-HCC, academic study of atezolizumab-bevacizumab vs TACE for intermediate stage #HCC.
Improved time to failure of treatment strategy with #systemic therapy.
Positive study, potential novel approach for #intermediate HCC
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
#ESMOAmbassadors: for the second year bringing you the life that is happening at #ESMO25.
✨ A heartfelt thank you to the #ESMOAmbassadors for their reporting on the latest in #CancerResearch & practice. Stay tuned!
#ONEoncologycommunity
Interested in or worried about #LargeLanguageModels in #ClinicalPractice? The @myesmo.bsky.social Guidance (#ELCAP) is out and ready for download!
#ESMO25 #ESMOAmbassadors
Delighted to be part of the #ESMOAmbassadors team at #ESMO25! 🌍
Let’s connect and discuss the latest news here in Berlin >>> and beyond!
#ONEOncologyCommunity
@myesmo.bsky.social
Stephen L. Chan discusses #CARES-009 and #SKYSCRAPER-14 phase 3 studies in #HCC at #ESMO25
#ESMOAmbassadors @myesmo.bsky.social
CARES-009 phase 3 study of perioperative camrelizumab and rivoceranib for #HCC
#ESMO25 #ESMOAmbassadors
@myesmo.bsky.social
Richard Finn presents the results of phase 3 IMbrave152/SkYSCRAPER-14 study at #ESMO25
Anti-TIGIT tiragolumab does not add benefit to atezolizumab-bevacizumab for patients with advanced #HCC
#ESMOAmbassadors @myesmo.bsky.social
HRS-4642 combined with chemo in advanced #KRAS-G12D mutant #PDAC
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Breaking the boundaries in pancreatic cancer #PDAC #surveillance #risk #liquidbiopsy #ctDNA #KRAS #noveltherapies
#ESMO25 #ESMOAmbassadors
@benwestphalen.bsky.social @myesmo.bsky.social
💥 Is it prime time for adoptive cell therapy in solid tumours?
📚 Special Educational Session on the state-of-the-art and future of cell therapies - evolving fast from promise to practice.
👀 Watch this space…
#ESMO25 #ESMOAmbassadors #CellTherapy #Immunotherapy
Matteo Simonelli presents the results for MK-1084 monotherapy in patients with #KRAS #G12C-mutated advanced solid tumors enrolled in the #phase1 KANDLELIT-001 study at #ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Please join the @myesmo.bsky.social Climate Change Task Force session on Saturday to learn more about climate conscious cancer care. #ESMO4Climate #ESMO25 #ESMOAmbassadors
On my way to #ESMO25!
I look forward to meeting friends and colleagues and discussing new data on hepatobiliary cancer #HCC #CCA #BTC.
#ESMOAmbassadors @myesmo.bsky.social
Proud to join such inspiring colleagues as an #ESMOAmbassadors
Excited for #ESMO25 and all the new #CancerResearch ahead.
@myesmo.bsky.social
Countdown to #ESMO25 now officially begins! Looking forward to all the breakthrough science and practice-changing data, and also reunion with my colleagues and friends. 🙌
#ESMOAmbassadors
#ESMO25: Do not miss the latest findings in #CancerResearch brought to you by the #ESMOAmbassadors & become part of the conversation in #oncology.
🔗 ow.ly/Tkr850X9A1a
Thank you @myesmo.bsky.social #ESMOGI2025 chairs & organizing committee to bring GI #rarecancers to the stage and having me in good company. I hope I brought some awareness to #appendixcancers #pseudomyxoma #peritonealmesothelioma
#ESMOAmbassadors
@acpmpresearch.bsky.social
#TeresaMacarulla nicely summarizes new data on #HPB cancers presented at #ESMOGI2025 #HCC #BTC #CCA #PDAC #ESMOAmbassadors @myesmo.bsky.social Post n.2
